Pharmaceutical Product Development, LLC (PPD) and Quotient Sciences have entered a new collaboration aimed at accelerating pediatric drug development by shortening timelines, reducing costs and simplifying contracting processes.

The partnership leverages PPD’s pediatric clinical trial experience, regulatory knowledge, and site and pediatric patient networks, and Quotient’s expertise in pediatric formulation development, drug product manufacturing and global supplies. The companies will jointly support pediatric drug development for clients from concept to market launch through an end-to-end service that aims to speed development. The new service is in response to key regulatory agencies promoting the development of new medicines for children earlier in the product development life cycle.

The collaboration simplifies contracting and delivery by offering clients a single source for an entire pediatric program, with one contract and one PPD point of contact. This aims to reduce the number of handoffs and streamline processes, helping to eliminate the delays that can occur when moving from early dosing to later phases.

“Our collaboration with Quotient will enable us to jointly provide a one-of-a-kind offering that meets the needs of patients and regulators in the development of pediatric drug products,” said Karen Kaucic, M.D., senior vice president, global head of PPD’s Rare Disease and Pediatric Center of Excellence. “For our customers, this integrated, full-service approach will provide accelerated timelines through a simple contracting process, the rapid development and clinical testing of pediatric formulations, and comprehensive program design and regulatory support. We believe the combined global expertise that our two companies can offer in formulation, manufacture and clinical development of pediatric medicines is a unique offering that will accelerate the development of these important products.”
           
“Our commitment to pediatric medicines has been building for several years,” said Mark Egerton, chief executive officer of Quotient. “Through our partnership with PPD, our customers can now access an end-to-end solution that can be tailored to their specific needs. PPD has built significant expertise and capabilities in delivering pediatric clinical trials, which we believe makes the partnership a natural fit for us.”